Excalipoint Therapeutics Launches, Will Develop Next-Gen T-Cell Engagers

Excalipoint Therapeutics, based in Shanghai, is launching with an oversubscribed $68.7 million seed financing round. The biotechnology company’s focus is developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases.

Funding will support advancement of Excalipoint’s proprietary technology platforms—namely, TOPAbody, T-Cell Immune Shield, and TCE Probody. Also, the financing addresses a pipeline of six differentiated programs with first- or best-in-class potential.

T-Cell Programs in Development

One of these programs is a tri-specific antibody to treat small-cell lung cancer, neuroendocrine tumors, and other malignancies. Excalipoint initiated a Phase I/II clinical trial for this program with the first patient dosed in October 2025.

Other pipeline programs are in development for treatment of colorectal, gastric, and pancreatic cancers, and tumors with high unmet need.

Excalipoint says its next-gen platforms intend to overcome traditional biological barriers in TCE therapies. Such issues include converting “cold” tumors into “hot,” challenges of the tumor microenvironment, and targeting difficult-to-drug tumor antigens.

Programs developed by these platforms, accordingly, aim to improve the efficacy, safety, and durability of T-cell immunotherapies. Going forward, Excalipoint hopes to reduce single-asset risk and drive the company’s value via strategic partnership and out-licensing.

How Excalipoint Was Funded

As for the financing breakdown, Excalipoint’s August 2025 inception accounted for some $41 million in seed funding. HSG, Apricot Capital, and Yuanbio Venture Capital co-led this funding. 5Y Capital, Co-Win Ventures, Med-Fine Capital and Hony Capital also participated.

Notably, Excalipoint says that seed round represented one of the largest early-stage financings for a Chinese biotech.

Following that, MPCi and Centurium Capital co-led a $27.7 million extension, with participation from Lilly Asia Ventures and Eisai Innovation.

Previously mentioned investors Apricot Capital and 5Y Capital also participated in the extension round.